UCLA launches joint venture with Chinese firm to open lab in Shanghai
April 8, 2014.
Clinical laboratory will provide more accurate diagnoses of cancer and other diseases.
Scott Binder, UCLA
The new company, CTI-Pathology/UCLA Health, is jointly owned by CTI and the University of California. The 25,000-square-foot facility — the first of its kind in China — will offer genetic and molecular diagnostics and other sophisticated tests that exceed the scope of the average lab in China, and UCLA pathologists will train Chinese lab specialists to accurately interpret the tests. The lab is expected to open in September.
The partnership is the first between a Chinese company and a U.S. academic medical center to create a specialized laboratory in China. The agreement was signed today at Ronald Reagan UCLA Medical Center in a ceremony that was videocast to China.
“This joint venture is founded on UCLA’s desire to build strong global relationships that, through education, research and service, improve the health of people and communities throughout the world,” said Dr. Tom Rosenthal, chief medical officer for UCLA Health System and co-director of UCLA’s Center for World Health. “UCLA has a genuine interest in elevating the level of medicine around the world. This is one way we can really make a difference in the quality of the Chinese people’s health care and lives.”
UCLA will oversee management of the laboratory to ensure that its operations meet international standards for quality, and CTI will provide capital funding and marketing expertise. The University of California Regents approved the joint venture on Jan. 22.
“We are extremely pleased that the UCLA Health System, UCLA Department of Pathology and the UC Regents agreed to partner with CTI to establish and manage our joint venture laboratory in Shanghai,” said Sangem Hsu, president of CTI. “Our collaboration will offer the people of China oncology, pathology and laboratory medicine services they can trust. Many of these services are not largely available in China and are needed by physicians and health care providers to accurately diagnose and treat their patients.”
The Shanghai laboratory will be electronically and digitally linked with UCLA — enabling physicians and patients to consult with UCLA pathologists — and with hospitals, clinics and other laboratories throughout China.
“CTI will be an outstanding partner in our effort to significantly improve patient care in China,” said Dr. Scott Binder, senior vice chair of pathology and laboratory medicine at the Geffen School of Medicine, and director of pathology laboratory services for UCLA Health System, which performs more than 7 million tests and diagnose more than 90,000 tissue specimens a year.
Jianyu Rao, UCLA
“In the past, Chinese medicine focused more on treatment than diagnosis,” said Rao, a professor of pathology and laboratory medicine at the Geffen School of Medicine and director of cytopathology at UCLA Health System. “Due to the rise of a more-informed middle class, the Chinese people are recognizing the importance of accurate diagnoses for their conditions.”
The partnership also has led to teaching exchanges between UCLA and China. UCLA has already hosted Chinese pathologists and technologists for training on specialized diagnostics for skin, blood and brain tissue and other areas. In turn, UCLA pathologists will travel to China to learn about diseases that are common there but rare in the U.S.
“Because pathology has a history of being undervalued in China, the country has a shortage of pathologists trained to diagnose and interpret complex test results in specialized fields of medicine,” Binder said. “Our partnership gives CTI and UCLA the opportunity to save lives by changing that.”
No comments:
Post a Comment